Champions Oncology (CSBR) Projected to Announce Earnings on Thursday

Champions Oncology (NASDAQ:CSBR) is expected to be issuing its Q4 2026 results after the market closes on Thursday, July 16th. Analysts expect Champions Oncology to post earnings of ($0.05) per share and revenue of $12.8860 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2026 earning results page for the latest details on the call scheduled for Wednesday, July 22, 2026 at 4:30 PM ET.

Champions Oncology Price Performance

CSBR opened at $6.12 on Thursday. The stock has a market cap of $85.01 million, a P/E ratio of -38.25 and a beta of 0.39. The stock’s 50 day simple moving average is $6.08 and its 200 day simple moving average is $6.27. Champions Oncology has a 1-year low of $5.50 and a 1-year high of $9.63.

Institutional Investors Weigh In On Champions Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Champions Oncology by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company’s stock valued at $2,158,000 after buying an additional 6,229 shares during the last quarter. Mink Brook Asset Management LLC purchased a new position in Champions Oncology during the fourth quarter worth $555,000. Acadian Asset Management LLC raised its holdings in shares of Champions Oncology by 28.7% in the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 8,814 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Champions Oncology in the first quarter worth $200,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Champions Oncology in the first quarter worth $201,000. Hedge funds and other institutional investors own 41.30% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings cut Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.